Research Article

Effects of Magnetically Guided, SPIO-Labeled, and Neurotrophin-3 Gene-Modified Bone Mesenchymal Stem Cells in a Rat Model of Spinal Cord Injury

Rui-Ping Zhang,¹ Ling-Jie Wang,¹ Sheng He,¹ Jun Xie,² and Jian-Ding Li¹

¹Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan 030001, China

²Department of Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, China

Correspondence should be addressed to Jun Xie; 1900547207@qq.com and Jian-Ding Li; 4617784@qq.com

Received 9 February 2015; Revised 30 March 2015; Accepted 31 March 2015

Academic Editor: Jianjun Guan

Copyright © 2016 Rui-Ping Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite advances in our understanding of spinal cord injury (SCI) mechanisms, there are still no effective treatment approaches to restore functionality. Although many studies have demonstrated that transplanting *NT3* gene-transfected bone marrow-derived mesenchymal stem cells (BMSCs) is an effective approach to treat SCI, the approach is often low efficient in the delivery of engrafted BMSCs to the site of injury. In this study, we investigated the therapeutic effects of magnetic targeting of *NT3* gene-transfected BMSCs via lumbar puncture in a rat model of SCI. With the aid of a magnetic targeting cells delivery system, we can not only deliver the engrafted BMSCs to the site of injury more efficiently, but also perform cells imaging in vivo using MR. In addition, we also found that this composite strategy could significantly improve functional recovery and nerve regeneration compared to transplanting *NT3* gene-transfected BMSCs without magnetic targeting system. Our results suggest that this composite strategy could be promising for clinical applications.

1. Introduction

On a worldwide scale, a total of 2.5 million people have suffered spinal cord injury (SCI), which has placed a significant burden on societal resources [1]. Over the past two decades, the understanding of the pathophysiology of SCI has been greatly improved, and significant advances have been made in approaches employing various cell types (e.g., embryonic stem cells, mesenchymal stem cells, and neural stem cells) for transplantation to treat SCI [2]. Many studies have focused on bone marrow mesenchymal stem cell (BMSC) transplantation for SCI because of the pluripotent differentiation capabilities of these cells [3] and because they are associated with fewer ethical issues. Engrafted BMSCs can promote nerve fiber regeneration and functional recovery in animal studies [4]. In addition, neurotrophins play a significant role in modulating neuronal survival, neurogenesis, and synapse formation following SCI [5]. These neurotrophins include brain-derived neurotrophic factor (BDNF), nerve

growth factor (NGF), neurotrophin-3 (*NT3*), neurotrophin-4/5 (*NT4/5*), and neurotrophin-6 (*NT6*), many of which can be secreted by BMSCs.

However, BMSC transplantation for SCI cannot always achieve the desired outcome, partly because the number of surviving transplanted cells in injured spinal cord lesions and the secreted neurotrophins can directly influence the effect of cell transplantation [6]. Therefore, we designed an approach that is able to not only improve the efficiency of the delivery of BMSCs to the site of injury but also promote the secretion of neurotrophins.

Magnetic targeting systems with magnetically labeled cells have been evaluated as a more efficient and effective method for the delivery of cells to target sites [6–10]. A previous study by our group demonstrated that transplantation of *NT3*-expressing BMSCs has beneficial effects on functional recovery and nerve regeneration after SCI in a rat model [11]. Therefore, we attempted to combine the two strategies for the treatment of SCI.

The present study was designed to evaluate the therapeutic effects of a magnetic targeting system guiding magnetically labeled BMSCs, combined with *NT3* gene overexpression, as a novel approach for the treatment of SCI.

2. Materials and Methods

This study was approved by the Institutional Animal Use and Care Committee of Shanxi Medical University. Eight-week-old female Sprague-Dawley rats (Animal Center of Chinese People's Army Military Medical and Scientific Academy, Beijing, China, SCXK2007-004) were used in our study.

2.1. BMSC Isolation and Culture. Donor rats were euthanized with an overdose of pentobarbital sodium administered via intraperitoneal injection. The tibiae and femurs, including both ends of the bones, were harvested. After the proximal and distal ends of the bones were removed, the bone marrow cavities were exposed and flushed repeatedly with 6 mL of Dulbecco's modified essential medium (DMEM; Hyclone, Logan, UT, USA) using a 25-gauge needle. The collected bone marrow suspension was seeded into 25 cm² culture flasks in DMEM containing 10% fetal bovine serum (Hyclone), penicillin (100 U/mL; Invitrogen, Carlsbad, CA, USA), and streptomycin (100 µg/mL, Invitrogen), and the suspension was cultured at 37°C in a 5% CO₂ incubator (NAPCO, Thermo Scientific, Waltham, MA, USA). After 48 h, nonadherent cells and tissue fragments were discarded by replacing the medium. The medium was subsequently changed at intervals of 2 or 3 days. At approximately 2 weeks after the initiation of seeding, the adherent cells usually reached confluence. Then, the cells were resuspended in a trypsin/EDTA solution (Hyclone, USA) and passaged 1:3 at a density of 6,000/cm². After the cells were passaged three times, BMSCs from passage 3 were used for the present study. Details of identification of BMSCs are provided as supplementary data (in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/2018474>).

2.2. Lentiviral Infection of BMSCs. The rat *NT3* gene (reference sequence: NM.031073.2) was synthesized by Nanjing GenScript Bioengineering Technology and Services Co., Ltd. (Nanjing, China), and was confirmed via sequencing. The target plasmids pLV.EX3d.P/puro-EF1α > *NT3* > IRES/DsRed Express2 and pLV.EX2d.P/puro-EF1α > DsRed Express2 were constructed by Cyagen Biosciences Inc. (Suzhou, China). The target plasmids, three helper plasmids (pLV/helper-SL3, pLV/helper-SL4, and pLV/helper-SL5) and Lipofectamine 2000 were used to create NT3-DsRed lentivirus and DsRed lentivirus in 293T cells. The titers of the *NT3*-DsRed lentivirus and the DsRed lentivirus ranged from 1 to 1.8 × 10⁸ TU/mL and 3.5 to 3.8 × 10⁸ TU/mL, respectively, and were determined by the plate counting test dilution method.

The packaged lentiviruses were added to passage 3 BMSCs with complete culture medium and then incubated at 37°C in a 5% CO₂ and 95% relative humidity incubator (NAPCO, Thermo Scientific, Waltham, MA, USA). After 16 h, the medium was replaced. After 48 h, the BMSCs

containing the *NT3*-DsRed or DsRed gene were harvested, and the *NT3*-DsRed and DsRed genes were detected using a fluorescence microscope (IX71, Olympus, Tokyo, Japan). The *NT3* gene was detected via real-time Q-PCR (AB7500, Applied Biosystems, USA).

2.3. BMSC Labeling with Superparamagnetic Iron Oxide (SPIO). In total, 25 µg Fe/mL SPIO (0.5 mmol/mL; Resovist, Schering, Germany) and 375 ng/mL poly-L-lysine (PLL; Sigma, USA) were added to the complete culture medium and incubated at room temperature for 60 min. Then, this medium was added to transfected BMSCs containing the *NT3*-DsRed gene. After the cells were cultured for 24 h at 37°C in a 5% CO₂ incubator, this medium was discarded. The BMSCs were subsequently washed 3 times with phosphate-buffered saline (PBS) to remove the unlabeled SPIO. Following trypsinization, the BMSCs were suspended in culture medium as the injection solution for transplantation. Details of induction of SPIO-labeled BMSCs are provided as supplementary data.

2.4. SCI Model Preparation. We used 8–10-week-old adult female Sprague-Dawley rats (weight 180–240 g) for the present *in vivo* study. After the rats were anesthetized via intraperitoneal injection of pentobarbital sodium (50 mg/kg), laminectomies were performed microscopically on the T7–8 vertebrae through the midline, with the dura mater intact. A weight-drop device was used to generate the SCI model [12]. To induce a contusion of the spinal cord, a 25 g metal rod with a 2 mm diameter was dropped from a height of 3 cm vertically onto the exposed spinal cord, after which the metal rod was immediately removed from the impact point. Simultaneously, the hind limbs of the rats relaxed completely after twitching, indicating that the SCI model had been successfully generated. Then, the incision was sutured tightly in layers. To prevent postoperative infection, the rats were given 2 × 10⁵ U of penicillin via intramuscular injection every day after surgery. In addition, manual emptying of the bladders of the rats after surgery was performed twice a day by squeezing the lower abdomen until recovery of the micturition reflex was observed. Rats without postoperative hind-limb paralysis were excluded from the present study.

2.5. Rat Group Allocation and Cell Transplantation via Lumbar Puncture (LP). One-week after operation, 36 rats were selected as recipients and were randomly assigned to the following 3 groups: (1) BMSC group (BMSC, *n* = 12); (2) *NT3*-BMSC group (*NT3*, *n* = 12); and (3) Magnet and *NT3*-BMSC group (M-*NT3*, *n* = 12). After the rats were anesthetized again, BMSCs were transplanted via lumbar puncture (LP) as described previously [13]. Briefly, the L5 spinous process and the L4–5 ligamentum flavum were partially resected, and the dura was exposed. Then, at the L4–L5 intervertebral space, a microsyringe was advanced into the subarachnoid space, and 40 µL of culture medium containing 1 × 10⁶ cells was injected into the CSF. In the *NT3* and M-*NT3* groups, the rats received SPIO-labeled *NT3*-BMSCs. In the BMSC group, the rats received unlabeled BMSCs. After injection, each rat was kept in the head-down position at

a 30° slope for approximately 30 min [8]. Additionally, a slab of neodymium magnet (0.57 T, length 10 mm, width 8 mm, and height 2 mm) was attached to the spine of the rats at the T7 level with medical adhesive tape in the M-NT3 group, whereas nothing was placed on the back of the rats in the other two groups. After 24 h, the magnets were removed.

2.6. Magnetic Resonance Imaging. After the magnets were removed, the rats were anesthetized via intraperitoneal injection of pentobarbital sodium (50 mg/kg), and MR imaging of the spinal cord was performed using a 1.5 T clinical MR imager (GE Medical System, Signa Infinity Twin Speed & Excite Technology, USA) with a circular surface coil (diameter 11 cm). Axial images were obtained using a standard T2-weighted turbo spin-echo sequence. The imaging sequence parameters were as follows: field of view (FOV), 80 × 80 mm²; slice thickness, 2 mm; spacing, 0.5 mm; base resolution matrix, 256 × 256; repetition time (TR), 2,000 ms; and effective echo time (TE), 70 ms. To quantify the signal intensity (SI) in the MR images of the injured spinal cord, signal to noise ratios (SNRs) were calculated as $SNR = S - S_b / SD$, where S represents the SI of the region of interest (ROI); S_b represents the mean SI of the background; and SD represents the standard deviation of the ROI [14].

2.7. Evaluation of Hind-Limb Motor Function. After transplantation, the hind-limb motor function of all of the rats was assessed using the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale [15]. The averaged BBB scores were recorded independently on days 1–7 and then every week up to the fifth week by two examiners who were not aware of the group allocation information.

2.8. Tissue Harvesting and Preparation for Histological Assessment. On day 35 after cell transplantation, the rats were perfused intracardially with 100 mL of normal saline (NS), followed by 4% paraformaldehyde in a state of deep anesthesia, through intraperitoneal injection of pentobarbital sodium (100 mg/kg). After the spinal cord tissues were dissected, they were placed in 4% paraformaldehyde overnight for postfixation and were then transferred successfully to 10% and 20% sucrose solutions overnight. Each of the spinal cord tissues at the lesion site was resected as a 10 mm long block. The obtained tissue blocks were frozen, and 20 μm and 5 μm thick longitudinal sections were then cut using a cryostat (CM3050, Leica, Wetzlar, Germany). Next, the sections were mounted on glass slides for histological assessment. For western blot analysis, the rats were not perfused, and the spinal cords tissues were freshly harvested.

2.9. Hematoxylin-Eosin (HE) Staining for Cystic Cavity Measurements. Five-micrometer-thick longitudinal sections were stained with HE for measurements of the cystic cavity. After the slices were fixed in cold acetone for 30 min, they were sequentially placed in xylene, ethanol, and distilled water. The slices were stained with hematoxylin for 5 min, rinsed with running water, and then placed in HCL-ethanol for 30 s. After the slices were soaked in running water for 15 min, they were counterstained in eosin and rinsed.

Finally, the slices were dehydrated in an ascending series of ethanol, cleared in xylene, air-dried, and enveloped with balata (Sinopharm, Shanghai, China). The area of the cystic cavity was measured using a phase-contrast microscope (E100, Nikon, Tokyo, Japan).

2.10. Immunofluorescence Staining. Five-micrometer-thick longitudinal frozen sections were used for immunofluorescence staining. After the slices were fixed in cold acetone for 30 min, they were immersed in 0.3% Triton X-100 for 30 min at room temperature and then treated with 10% goat serum for 1 h at room temperature. Next, the slices were incubated overnight at 4°C with a primary antibody against either neurofilament-200 (NF200) or glial fibrillary acidic protein (GFAP) and then incubated for 1 h at room temperature with a secondary goat anti-mouse antibody (DyLight 488 AffiniPure, Earthox Biotechnology, San Francisco, CA, USA). After the slices were rinsed, they were enveloped with DAPI, and 10 min later, the slices were observed under a fluorescence microscope (IX70, Olympus).

2.11. Prussian Blue Staining. To identify iron particles in the SPIO-labeled cells, Prussian blue staining was performed on adjacent sections of the same spinal cord tissues. After the slices were fixed in cold acetone for 30 min, they were incubated in Perl's solution for 30 min at 37°C. Next, the slices were cooled, washed three times with PBS, and then counterstained with nuclear fast red. After the slices were washed and air-dried, they were enveloped with balata.

2.12. Statistical Analysis. All results are presented as the means ± standard deviation (SD). The BBB scores were analyzed through repeated measures analysis of variance (ANOVA). The data obtained from Prussian blue staining were analyzed with the Mann-Whitney U test. All other data were analyzed using one-way ANOVA to identify significant differences among the three groups. Statistical significance was inferred when the p value was less than 0.05. All statistical analyses were performed using the SAS 6.12 software program (SAS Institute, Cary, NC, USA).

3. Results

3.1. In Vitro Expression of DsRed and NT3 in BMSCs. After puromycin screening, red fluorescence was identified in the cytoplasm of >95% of the NT3-DsRed BMSCs and >99% of the DsRed BMSCs (Figure 1), which indicated a high transfection efficiency for BMSCs in the present study.

NT3 mRNA expression was assessed via real-time Q-PCR (Figure 1). The NT3 mRNA expression levels in the DsRed BMSCs and untransfected BMSCs were nearly equal. The NT3 mRNA expression level in the NT3-DsRed BMSCs was approximately 13-fold that in the DsRed BMSCs or untransfected BMSCs.

3.2. Successful Labeling of BMSCs with SPIO. After the BMSCs were labeled with SPIO, Prussian blue staining was performed to identify the SPIO labeling rate of BMSCs. Blue

FIGURE 1: Stable transfection of the *NT3-DsRed* gene into BMSCs using a lentivirus ((a), (b)) and Q-PCT detection of *NT3* mRNA ((c), (d)). (a) Before transfection. (b) After transfection. (c) *NT3* mRNA Q-PCR melting curve. (d) The normalized fold change in *NT3* mRNA expression ($2^{-\Delta\Delta CT}$). Magnification, $\times 100$ ((a), (b)). Scale bar, $100\ \mu\text{m}$ ((a), (b)).

FIGURE 2: Prussian blue staining of the SPIO-labeled and gene-transfected BMSCs ((a), (b)). Magnification, $\times 100$ (a), $\times 400$ (b). Scale bar, $200\ \mu\text{m}$ (a), $50\ \mu\text{m}$ (b).

iron particles were observed in the cytoplasm of the SPIO-labeled BMSCs, and the SPIO labeling rate of the BMSCs was nearly 100% (Figure 2).

3.3. MR Imaging after Cell Transplantation. The SI was obtained using $T2^*$ -weighted gradient-echo sequences in the injured spinal cord because $T2^*$ -weighted imaging is sensitive to SPIO (Figure 3). The injured spinal cord SIs of

the M-*NT3* and *NT3* groups decreased after transplantation, whereas no apparent change in the SI was observed in the BMSC group. Analysis of the SNR further revealed that the injured spinal cord SNRs of the M-*NT3* group were significantly decreased compared with those of the *NT3* group, and the SNRs for the injured spinal cords of the *NT3* group were significantly decreased compared with those of the BMSC group.

FIGURE 3: T2*-weighted MR images of the injured spinal cord on day 1 after cell transplantation in the BMSC group (a), NT3 group (b), and M-NT3 group (c). A bar graph showing the SNRs in the injured spinal cord MR images from each group (d). The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using one-way ANOVA. * $p < 0.05$ versus the BMSC group, # $p < 0.05$ versus the NT3 group.

3.4. Locomotor Behavioral Assessment. The hind-limb locomotor functions in each group were assessed using the BBB scores on days 1, 3, 7, 14, 21, 28, and 35 after cell transplantation (Figure 4). On days 1 and 3 after cell transplantation, the BBB scores of the M-NT3 group did not improve significantly compared with those of the other two groups. However, the BBB scores of the M-NT3 group were the highest among the three groups on days 7, 14, 21, 28, and 35 after cell transplantation, which indicated that hind-limb locomotor functional recovery was enhanced and accelerated in the M-NT3 group compared with the other two groups. The BBB scores of the NT3 group were also significantly higher than those of the BMSC group on days 7, 14, 21, 28, and 35 after cell transplantation. Moreover, significant differences ($p < 0.05$) were observed among the three groups at these time points.

3.5. Prussian Blue Staining of the Injured Spinal Cord Tissues. After Prussian blue staining was performed on the injured spinal cord tissue sections, significantly more blue-stained cells were observed in the M-NT3 group than in the NT3 group, whereas no blue-stained cells could be observed in the BMSC group (Figure 5).

3.6. Cystic Cavity Area Measurements. At 7 weeks after the spinal cord was injured, the mean values of the cystic cavity

area in the BMSC, NT3, and M-NT3 groups were $0.64 \pm 0.14 \text{ mm}^2$, $0.51 \pm 0.11 \text{ mm}^2$, and $0.39 \pm 0.10 \text{ mm}^2$, respectively. Statistically significant differences were observed among the three groups ($p < 0.05$, Figure 6), with the cystic cavity area in the M-NT3 group being the smallest.

3.7. Expression of the NT3 Protein in the Injured Spinal Cord after Cell Transplantation. On day 35 after cell transplantation, NT3 protein expression was investigated through western blot analysis (Figure 7). Although NT3 protein overexpression was observed in both the M-NT3 group and the NT3 group, the NT3 protein level in the M-NT3 group was significantly higher than in the NT3 group. In addition, the NT3 protein level in the BMSC group was significantly lower than in the NT3 group. The magnetic targeting system significantly enhanced NT3 protein expression in the injured spinal cord lesions.

3.8. Axon Regeneration and Glial Scar Inhibition in the Injured Spinal Cord. NF200 is a NF protein that is found in axons under normal conditions [16]. Increased expression of NF200 indicates axon regeneration in the injured spinal cord. In contrast, GFAP is expressed primarily in astrocytes, and a reduction of its expression indicates glial scar inhibition

FIGURE 4: The BBB scores of the hind-limb locomotor functions in each group on days 1, 3, 7, 14, 21, 28, and 35 after cell transplantation ((a), (b)). The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using repeated measures ANOVA. * $p < 0.05$ versus the BMSC group, # $p < 0.05$ versus the NT3 group.

FIGURE 5: Prussian blue staining of tissues around the injured spinal cord lesion on day 35 after transplantation in the BMSC group (a), NT3 group (b), and M-NT3 group (c). Magnification, $\times 200$ ((a), (b), and (c)). Scale bar, 100 μ m ((a), (b), and (c)). (d) The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using the Mann-Whitney U test. # $p < 0.05$ versus the NT3 group.

FIGURE 6: The cystic cavity area of the injured spinal cords on day 35 after cell transplantation in the BMSC group (a), NT3 group (b), and M-NT3 group (c). Magnification, $\times 40$ ((a), (b), and (c)). Scale bar, 200 μ m ((a), (b), and (c)). The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using one-way ANOVA. * $p < 0.05$ versus the BMSC group, # $p < 0.05$ versus the NT3 group.

FIGURE 7: Western blot detection of NT3 protein expression in the injured spinal cords on day 35 after cell transplantation in each group (a). Ratio of the lane density of the NT3 protein to the lane density of the β -actin protein in each group (b). The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using one-way ANOVA. * $p < 0.05$ versus the BMSC group, # $p < 0.05$ versus the NT3 group.

FIGURE 8: Immunofluorescence labeling of NF200 ((a), (b), and (c)) and GFAP ((e), (f), and (g)) in sagittal sections of the injured spinal cords from each group on day 35 after cell transplantation. Double labeling for NF200/GFAP (green) and BMSCs (red). Magnification, $\times 400$ ((a)–(c), (e)–(g)). Scale bar, $50\ \mu\text{m}$ ((a)–(c), (e)–(g)). Integrated optical density (IOD) bar graphs showing NF200 (g) and GFAP (h) expression in each group. All microscopic images were captured under identical conditions. The data, which are presented as the means $\pm$ SD ($n = 12$), were analyzed using one-way ANOVA. * $p < 0.05$ versus the BMSC group, # $p < 0.05$ versus the NT3 group.

in the injured spinal cord. As shown in Figure 8, the level of NF200 expression in the M-NT group was significantly increased compared with that in the other two groups, whereas the GFAP expression level in the M-NT group was significantly decreased compared with that in the other two groups. Moreover, the NF200 expression level in the NT3 group was higher than in the BMSC group, whereas the GFAP expression level in the NT3 group was lower than in the BMSC group.

4. Discussion

In the present study, we investigated the effects of a magnet-guided SPIO-labeled BMSC transplantation method combined with gene therapy for the treatment of spinal cord injury in rats. We found that this approach not only was more effective for repairing SCI but also allowed the engrafted cells to be tracked in vivo.

SCI is a complex pathological process for which effective treatment strategies are currently lacking [17]. Cell replacement therapy is a promising approach for repairing the injured spinal cord. In particular, BMSCs have been extensively studied in animal models of SCI because these cells are easily isolated and cultured, exhibit pluripotent differentiation capabilities, and are associated with fewer ethical issues [2, 3, 8, 18, 19]. Although many experimental studies have demonstrated that BMSC transplantation can promote nerve regeneration and enhance functional recovery in animal models of SCI [20], the desired outcome (full recovery) cannot be obtained. The possible reasons for these

poor outcomes include the lack of adequate neurotrophic factors and surviving stem cells in injured spinal cord lesions.

Neurotrophic factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), neurotrophin-4/5 (NT4/5), and neurotrophin-6 (NT6), play crucial roles in nerve regeneration after SCI [21, 22]. Although BMSCs can express many neurotrophic factors in vitro [23, 24], engrafted BMSCs do not express NT3 in vivo [23, 25, 26]. However, NT3 is an extremely important neuroregenerative protein involved in guiding stem cell migration, mediating engrafted BMSC survival, inducing neuronal differentiation, promoting axonal regeneration, and facilitating angiogenesis after SCI [22, 27–31]. Considering these NT3 protein activities, stably NT3-transfected BMSCs were obtained using lentivirus vectors to produce BMSCs that could overexpress the NT3 protein in vivo.

The present study showed that stable transfection of BMSCs with the NT3 gene was possible, and the resulting cells were more effective than conventional BMSCs in vivo for promoting axonal regeneration, enhancing functional recovery, and maintaining the survival of engrafted cells. Although the NT3 protein could be detected in the BMSC group, it was expressed at a much lower level than in the other two groups. This low-level expression may be attributed to the presence of inflammatory cells (i.e., macrophages, lymphocytes, and mast cells), microglia/macrophages, astrocytes, oligodendrocytes, and neural progenitor cells that are present following spinal cord injury and can express the NT3 protein [32–36]. All of these findings are consistent with a previous study by our group [11]. In addition, our previous study demonstrated that

NT3 gene-modified BMSC transplantation was superior to BMSC transplantation in promoting neuronal regeneration, inhibiting glial scar formation, and increasing BDNF and VEGF secretion after SCI [11].

The survival of the engrafted stem cells in the lesion has a direct effect on the repair outcome of stem cell transplantation strategies [6, 37]. Although BMSCs have been shown to home to injured spinal cord lesions [38, 39], this homing effect does not result in an adequate number of BMSCs homing to the lesion for clinical efficacy. Direct injection, lumbar subdural injection, and intravessel injection are the traditional methods used for cell transplantation. Many recent studies have shown that lumbar subdural injection is a safe, less invasive (compared to the other methods), and repeatable method of cell transplantation [8, 13, 40, 41]. However, the direct injection of cells is more efficient than lumbar subdural injection [8], although this method is more invasive than intravessel injection.

A highly efficient and less invasive cell delivery system is particularly important for cell transplantation to treat SCI. To achieve a compromise between efficiency and invasiveness, we chose to transplant cells via lumbar subdural injection in the present study. To improve the efficiency of cell delivery, a magnetic targeting system was used. Some previous studies demonstrated that SPIO-labeled BMSCs transplanted via lumbar puncture were delivered to the spinal cord injury site efficiently through the CSF using a magnetic targeting system [6, 8, 10]. In addition, SPIO nanoparticles can significantly shorten T1 and T2 relaxation times and particularly the T2* relaxation time. Therefore, SPIO nanoparticles can cause a significant reduction of the T2* SI observed under MRI. In the present study, many more blue-stained cells could be observed following Prussian blue staining, and the injured spinal cord SNRs of the T2*-weighted MR images were significantly decreased in the magnet group compared with the other two nonmagnet groups; both of these findings indicated that more BMSCs homed to the injured spinal cord lesions in the magnet group than in the other two, nonmagnet groups.

NF200 is one of the NF proteins that can be found in axons under normal conditions [15]. After SCI, astrogliosis will increase GFAP expression following glial scar formation in the lesion. The immunofluorescence experiments performed in the present study showed that NF200 expression around the injured site was much higher in the magnet group than in the other two, nonmagnet groups, whereas GFAP expression around the injured site was much lower in the magnet group than in the other two, nonmagnet groups. These findings indicate that transplantation of *NT3* gene-modified BMSCs with the aid of a magnetic targeting system can significantly promote neuronal regeneration and inhibit glial scar formation.

Locomotor testing was also performed in the present study to assess hind-limb motor function using the BBB score. At day 35 after cell transplantation, the BBB scores of the magnet group did not appear to be markedly improved compared with the *NT3*-BMSC group from our previous study [11], which was mainly attributed to the different researchers involved in the two studies and the subjectivity

of the BBB scoring system. Although the BBB scores of the magnet group were improved by only approximately 10% at day 35 after cell transplantation in the present study, the dynamic variation of BBB scores in the three groups indicated that hind-limb locomotor functional recovery was enhanced and accelerated in the magnet group compared with the other two, nonmagnet groups. All of these findings could be attributed primarily to the magnetic targeting system effectively delivering the engrafted BMSCs to the injured spinal cord lesion [10].

In summary, the present study demonstrated that the Magnet-*NT3* group showed a significantly better efficiency of cell delivery, nerve regeneration, and functional recovery than the *NT3*-BMSC group. Thus, transplantation of *NT3* gene-modified BMSCs via lumbar puncture combined with a magnetic targeting system is a highly effective and minimally invasive therapeutic method for treating spinal cord injury and is promising for monitoring engrafted BMSCs in vivo through MR.

Disclosure

Rui-Ping Zhang and Ling-Jie Wang are co-first authors.

Conflict of Interests

There is no conflict of interests to declare.

Authors' Contribution

Rui-Ping Zhang and Ling-Jie Wang contributed equally to this work.

Acknowledgments

This study was supported by grants from the Scientific and Technological Projects of Shanxi Province (20120321028-02) to Rui-Ping Zhang, from the China Postdoctoral Foundation to Rui-Ping Zhang (2013M541206 and 2014T70233), and from the NSFC (National Nature Science Foundation of People's Republic of China, 81371628) to Jian-Ding Li.

References

- [1] M. G. Fehlings, J. R. Wilson, and M. O'Higgins, "Introduction: spinal cord injury at the cutting edge of clinical translation: a focus issue collaboration between NACTN and AOSpine North America," *Journal of Neurosurgery. Spine*, vol. 17, no. 1, pp. 1–3, 2012.
- [2] A. M. Parr, I. Kulbatski, X.-H. Wang, A. Keating, and C. H. Tator, "Fate of transplanted adult neural stem/progenitor cells and bone marrow-derived mesenchymal stromal cells in the injured adult rat spinal cord and impact on functional recovery," *Surgical Neurology*, vol. 70, no. 6, pp. 600–607, 2008.
- [3] C. D. Porada, E. D. Zanjani, and G. Almeida-Porad, "Adult mesenchymal stem cells: a pluripotent population with multiple applications," *Current Stem Cell Research and Therapy*, vol. 1, no. 3, pp. 365–369, 2006.

- [4] C. P. Hofstetter, E. J. Schwarz, D. Hess et al., "Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 4, pp. 2199–2204, 2002.
- [5] G. C. Sieck and C. B. Mantilla, "Role of neurotrophins in recovery of phrenic motor function following spinal cord injury," *Respiratory Physiology & Neurobiology*, vol. 169, no. 2, pp. 218–225, 2009.
- [6] V. Vaněček, V. Zablotskii, S. Forostyak et al., "Highly efficient magnetic targeting of mesenchymal stem cells in spinal cord injury," *International Journal of Nanomedicine*, vol. 7, pp. 3719–3730, 2012.
- [7] R. Egle, M. Milek, I. Mlinarič-Raščan, A. Fahr, and J. Kristl, "A novel gene delivery system for stable transfection of thiopurine-S-methyltransferase gene in versatile cell types," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 69, no. 1, pp. 23–30, 2008.
- [8] K. Nishida, N. Tanaka, K. Nakanishi et al., "Magnetic targeting of bone marrow stromal cells into spinal cord: through cerebrospinal fluid," *NeuroReport*, vol. 17, no. 12, pp. 1269–1272, 2006.
- [9] T. Hamasaki, N. Tanaka, N. Kamei et al., "Magnetically labeled neural progenitor cells, which are localized by magnetic force, promote axon growth in organotypic cocultures," *Spine*, vol. 32, no. 21, pp. 2300–2305, 2007.
- [10] H. Sasaki, N. Tanaka, K. Nakanishi et al., "Therapeutic effects with magnetic targeting of bone marrow stromal cells in a rat spinal cord injury model," *Spine*, vol. 36, no. 12, pp. 933–938, 2011.
- [11] L.-J. Wang, R.-P. Zhang, and J.-D. Li, "Transplantation of neurotrophin-3-expressing bone mesenchymal stem cells improves recovery in a rat model of spinal cord injury," *Acta Neurochirurgica*, vol. 156, no. 7, pp. 1409–1418, 2014.
- [12] S. Constantini and W. Young, "The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats," *Journal of Neurosurgery*, vol. 80, no. 1, pp. 97–111, 1994.
- [13] A. Bakshi, C. Hunter, S. Swanger, A. Lepore, and I. Fischer, "Minimally invasive delivery of stem cells for spinal cord injury: advantages of the lumbar puncture technique," *Journal of Neurosurgery: Spine*, vol. 1, no. 3, pp. 330–337, 2004.
- [14] R. R. Price, L. Axel, T. Morgan et al., "Quality assurance methods and phantoms for magnetic resonance imaging: report of AAPM nuclear magnetic resonance Task Group No. 1," *Medical Physics*, vol. 17, no. 2, pp. 287–295, 1990.
- [15] D. M. Basso, M. S. Beattie, and J. C. Bresnahan, "A sensitive and reliable locomotor rating scale for open field testing in rats," *Journal of Neurotrauma*, vol. 12, no. 1, pp. 1–21, 1995.
- [16] W.-G. Liu, Z.-Y. Wang, and Z.-S. Huang, "Bone marrow-derived mesenchymal stem cells expressing the bFGF transgene promote axon regeneration and functional recovery after spinal cord injury in rats," *Neurological Research*, vol. 33, no. 7, pp. 686–693, 2011.
- [17] J. Shen, X.-M. Zhong, X.-H. Duan et al., "Magnetic resonance imaging of mesenchymal stem cells labeled with dual (MR and fluorescence) agents in rat spinal cord injury," *Academic Radiology*, vol. 16, no. 9, pp. 1142–1154, 2009.
- [18] E. Syková and P. Jendelová, "Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord," *Annals of the New York Academy of Sciences*, vol. 1049, pp. 146–160, 2005.
- [19] M. Chopp and Y. Li, "Treatment of neural injury with marrow stromal cells," *Lancet Neurology*, vol. 1, no. 2, pp. 92–100, 2002.
- [20] S. Wu, Y. Suzuki, Y. Ejiri et al., "Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord," *Journal of Neuroscience Research*, vol. 72, no. 3, pp. 343–351, 2003.
- [21] J. L. Goldberg and B. A. Barres, "The relationship between neuronal survival and regeneration," *Annual Review of Neuroscience*, vol. 23, pp. 579–612, 2000.
- [22] A. Patapoutian and L. F. Reichardt, "Trk receptors: mediators of neurotrophin action," *Current Opinion in Neurobiology*, vol. 11, no. 3, pp. 272–280, 2001.
- [23] L. Crigler, R. C. Robey, A. Asawachaicharn, D. Gaupp, and D. G. Phinney, "Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurogenesis," *Experimental Neurology*, vol. 198, no. 1, pp. 54–64, 2006.
- [24] B. Neuhuber, B. Timothy Himes, J. S. Shumsky, G. Gallo, and I. Fischer, "Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations," *Brain Research*, vol. 1035, no. 1, pp. 73–85, 2005.
- [25] M. M. Yaghoobi and S. J. Mowla, "Differential gene expression pattern of neurotrophins and their receptors during neuronal differentiation of rat bone marrow stromal cells," *Neuroscience Letters*, vol. 397, no. 1–2, pp. 149–154, 2006.
- [26] N. Kamei, N. Tanaka, Y. Oishi et al., "Bone marrow stromal cells promoting corticospinal axon growth through the release of humoral factors in organotypic cocultures in neonatal rats," *Journal of Neurosurgery: Spine*, vol. 6, no. 5, pp. 412–419, 2007.
- [27] M. Douglas-Escobar, C. Rossignol, D. Steindler, T. Zheng, and M. D. Weiss, "Neurotrophin-induced migration and neuronal differentiation of multipotent astrocytic stem cells *in vitro*," *PLoS ONE*, vol. 7, no. 12, Article ID e51706, 2012.
- [28] A. D. Pyle, L. F. Lock, and P. J. Donovan, "Neurotrophins mediate human embryonic stem cell survival," *Nature Biotechnology*, vol. 24, no. 3, pp. 344–350, 2006.
- [29] Z.-H. Zhang, R.-Z. Wang, G.-L. Li et al., "Transplantation of neural stem cells modified by human neurotrophin-3 promotes functional recovery after transient focal cerebral ischemia in rats," *Neuroscience Letters*, vol. 444, no. 3, pp. 227–230, 2008.
- [30] B. Cristofaro, O. A. Stone, A. Caporali et al., "Neurotrophin-3 is a novel angiogenic factor capable of therapeutic neovascularization in a mouse model of limb ischemia," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 6, pp. 1143–1150, 2010.
- [31] I. Jean, C. Lavialle, A. Barthelaix-Pouplard, and C. Fressinaud, "Neurotrophin-3 specifically increases mature oligodendrocyte population and enhances remyelination after chemical demyelination of adult rat CNS," *Brain Research*, vol. 972, no. 1–2, pp. 110–118, 2003.
- [32] M. Besser and R. Wank, "Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors," *Journal of Immunology*, vol. 162, no. 11, pp. 6303–6306, 1999.
- [33] M. A. Laurenzi, G. Barbany, T. Timmusk, J. A. Lindgren, and H. Persson, "Expression of mRNA encoding neurotrophins and neurotrophin receptors in rat thymus, spleen tissue and immunocompetent cells. Regulation of neurotrophin-4 mRNA expression by mitogens and leukotriene B₄," *European Journal of Biochemistry*, vol. 223, no. 3, pp. 733–741, 1994.

- [34] A. G. Rabchevsky and W. J. Streit, "Role of microglia in post injury repair and regeneration of the CNS," *Mental Retardation and Developmental Disabilities Research Reviews*, vol. 4, no. 3, pp. 187–192, 1998.
- [35] K. D. Dougherty, C. F. Dreyfus, and I. B. Black, "Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury," *Neurobiology of Disease*, vol. 7, no. 6, pp. 574–585, 2000.
- [36] N. Kamei, N. Tanaka, Y. Oishi et al., "BDNF, NT-3, and NGF released from transplanted neural progenitor cells promote corticospinal axon growth in organotypic cocultures," *Spine*, vol. 32, no. 12, pp. 1272–1278, 2007.
- [37] E.-S. Kang, K.-Y. Ha, and Y.-H. Kim, "Fate of transplanted bone marrow derived mesenchymal stem cells following spinal cord injury in rats by transplantation routes," *Journal of Korean Medical Science*, vol. 27, no. 6, pp. 586–593, 2012.
- [38] B.-R. Son, L. A. Marquez-Curtis, M. Kucia et al., "Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases," *Stem Cells*, vol. 24, no. 5, pp. 1254–1264, 2006.
- [39] J. F. Ji, J. B. P. He, S. T. Dheen, and S. S. W. Tay, "Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury," *Stem Cells*, vol. 22, no. 3, pp. 415–427, 2004.
- [40] M. Ohta, Y. Suzuki, T. Noda et al., "Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation," *Experimental Neurology*, vol. 187, no. 2, pp. 266–278, 2004.
- [41] K. Satake, J. Lou, and L. G. Lenke, "Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue," *Spine*, vol. 29, no. 18, pp. 1971–1979, 2004.